V Le Cam-Duchez1, A Bagan-Triquenot, V Barbay, B Mihout, J Y Borg. 1. Unité Fonctionnelle d'Hémostase Vasculaire, Hématologie Biologique, CHU de Rouen - Hôpital Charles Nicolle, 1, rue de Germont, 76031, Rouen Cedex, France.
Abstract
BACKGROUND AND PURPOSE: Protein Z (PZ), a vitamin Kdependent protein, plays a role in inhibiting coagulation. Its plasma level or PZ gene polymorphisms have been discussed as risk factors for stroke with conflicting results reported between various studies. Only one of these polymorphisms was studied in a cohort of patients suffering from cerebral venous thrombosis (CVT). METHODS: We performed a retrospective genetic study comparing 100 healthy controls to 54 patients referred to our hemostasis unit after CVT occurrence. We compared the distribution of three PZ gene polymorphisms that may influence PZ plasma levels: A-13G in the promoter and G79A in intron F were tested using previously described techniques, and we developed a technique to evaluate the G-103A in intron A. RESULTS: The G79A polymorphism was significantly more frequent in patients than in controls (p = 0.012): the presence of at least one A allele led to an odds ratio of 2.57 with a 95 % confidence interval of 1.23-5.34. The A-13G polymorphism also showed a nonsignificant trend towards a higher prevalence in patients. CONCLUSION: The G79A polymorphism of the PZ gene was shown to be a new independent risk factor for cerebral venous thrombosis. Nevertheless, these results have to be confirmed by a prospective study including plasma PZ evaluation.
BACKGROUND AND PURPOSE: Protein Z (PZ), a vitamin Kdependent protein, plays a role in inhibiting coagulation. Its plasma level or PZ gene polymorphisms have been discussed as risk factors for stroke with conflicting results reported between various studies. Only one of these polymorphisms was studied in a cohort of patients suffering from cerebral venous thrombosis (CVT). METHODS: We performed a retrospective genetic study comparing 100 healthy controls to 54 patients referred to our hemostasis unit after CVT occurrence. We compared the distribution of three PZ gene polymorphisms that may influence PZ plasma levels: A-13G in the promoter and G79A in intron F were tested using previously described techniques, and we developed a technique to evaluate the G-103A in intron A. RESULTS: The G79A polymorphism was significantly more frequent in patients than in controls (p = 0.012): the presence of at least one A allele led to an odds ratio of 2.57 with a 95 % confidence interval of 1.23-5.34. The A-13G polymorphism also showed a nonsignificant trend towards a higher prevalence in patients. CONCLUSION: The G79A polymorphism of the PZ gene was shown to be a new independent risk factor for cerebral venous thrombosis. Nevertheless, these results have to be confirmed by a prospective study including plasma PZ evaluation.
Authors: C Lichy; S Kropp; T Dong-Si; J Genius; T Dolan; T Hampe; F Stoll; K Reuner; C Grond-Ginsbach; A Grau Journal: Stroke Date: 2003-12-11 Impact factor: 7.914
Authors: K H Reuner; E Jenetzky; A Aleu; F Litfin; P Mellado; M Kloss; E Jüttler; A J Grau; H Rickmann; H Patscheke; C Lichy Journal: Neurology Date: 2008-01-08 Impact factor: 9.910
Authors: Ioana Cotlarciuc; Thomas Marjot; Muhammad S Khan; Sini Hiltunen; Elena Haapaniemi; Tiina M Metso; Jukka Putaala; Susanna M Zuurbier; Matthijs C Brouwer; Serena M Passamonti; Paolo Bucciarelli; Emanuela Pappalardo; Tasmin Patel; Paolo Costa; Marina Colombi; Patrícia Canhão; Aleksander Tkach; Rosa Santacroce; Maurizio Margaglione; Giovanni Favuzzi; Elvira Grandone; Donatella Colaizzo; Kostas Spengos; Antonio Arauz; Amanda Hodge; Reina Ditta; Stephanie Debette; Marialuisa Zedde; Guillaume Pare; José M Ferro; Vincent Thijs; Alessandro Pezzini; Jennifer J Majersik; Ida Martinelli; Jonathan M Coutinho; Turgut Tatlisumak; Pankaj Sharma Journal: BMJ Open Date: 2016-11-22 Impact factor: 2.692